Neuro-oncological and neurodegenerative disorders, represented paradigmatically by glioblastoma and Alzheimer's disease, respectively, persist as formidable challenges in the biomedical realm. The interconnected molecular underpinnings of these conditions necessitate rigorous and novel therapeutic examinations. This comprehensive research was anchored on the premise of unveiling the therapeutic potential and specificity of Lupenone, a potent phytoconstituent, in targeting the molecular pathways underpinning both glioblastoma and Alzheimer's amyloid beta pathology. This was gauged through its interactions with key protein structures, 5H08 and 2ZHV. An integrative approach was adopted, marrying advanced proteomics and modern computer-aided drug design techniques. Molecular docking of Lupenone with 5H08 and 2ZHV was meticulously executed, with subsequent molecular dynamics simulations providing insights into the stability, viability, and intricacies of these interactions. Lupenone demonstrated profound binding affinities, evidenced by robust docking scores of -9.54 kcal/mol for 5H08 and -10.59 kcal/mol for 2ZHV. These interactions underscored Lupenone's eminent therapeutic potential in mitigating glioblastoma and modulating the amyloid beta pathology inherent to Alzheimer's. The introduction of Proteolysis Targeting Chimeras (PROTACs) further magnified the therapeutic prospects, accentuating Lupenone's efficacy. The findings of this study not only underscore the therapeutic acumen of Lupenone in addressing the challenges posed by glioblastoma and Alzheimer's but also lay a strong foundation for its consideration as a leading candidate in future neuro-oncological and neurodegenerative research endeavors. Given the compelling in-silico data, a clarion call is made for its empirical validation in holistic in-vivo settings, potentially pioneering a new therapeutic epoch in both glioblastoma and Alzheimer's interventions.

神经肿瘤和神经退行性疾病，分别以胶质母细胞瘤和阿尔茨海默病为代表，一直是生物医学领域的巨大挑战。这些病症相互关联的分子基础需要严格而新颖的治疗检查。这项综合研究的前提是揭示了羽扇豆酮（一种有效的植物成分）在靶向胶质母细胞瘤和阿尔茨海默氏症淀粉样蛋白病理学的分子途径方面的治疗潜力和特异性。这是通过其与关键蛋白质结构 5H08 和 2ZHV 的相互作用来衡量的。采用了综合方法，将先进的蛋白质组学和现代计算机辅助药物设计技术结合起来。羽扇豆酮与 5H08 和 2ZHV 的分子对接经过精心执行，随后的分子动力学模拟提供了对这些相互作用的稳定性、可行性和复杂性的见解。羽扇豆酮表现出深刻的结合亲和力，5H08 的强大对接分数为 -9.54 kcal/mol，2ZHV 的对接分数为 -10.59 kcal/mol。这些相互作用强调了羽扇豆酮在减轻胶质母细胞瘤和调节阿尔茨海默病固有的β淀粉样蛋白病理学方面的卓越治疗潜力。蛋白水解靶向嵌合体 (PROTAC) 的引入进一步放大了治疗前景，增强了羽扇豆酮的功效。这项研究的结果不仅强调了羽扇豆酮在应对胶质母细胞瘤和阿尔茨海默氏症带来的挑战方面的治疗敏锐性，而且还为其被视为未来神经肿瘤学和神经退行性研究努力的领先候选者奠定了坚实的基础。鉴于令人信服的计算机数据，人们强烈呼吁其在整体体内环境中进行实证验证，这可能会开创胶质母细胞瘤和阿尔茨海默病干预的新治疗时代。